Novartis (NVS) reviewing units that don't have "global scale and critical mass." The company's pharmaceutical, Alcon eyecare and Sandoz generics divisions fulfill these requirements; in the other businesses, Novartis is "looking at ways to either strengthen them or to think about other opportunities," says CEO Joseph Jimenez.
Sales breakdown: Pharmaceuticals +1% to $7.9B, boosted by higher prices and sales volume; Alcon +3% to $2.5B, helped by sales of surgical products; Sandoz +11% to $2.3B, pushed up by the acquisition of Fougera in 2012. Vaccines +2% to $594M; consumer health +11% to $1B.
Shares +0.9% in Zurich. (Previous) (PR)